Supplementary Figures S1-S7 from Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody–Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure S1. Retention of MEDI3726 activity in human, cynomolgus monkey plasma or PBS for up to 7 days. Supplementary Figure S2. Kaplan-Meier analysis of the Time-to-Endpoint Survival in the (A) LNCaP, (B) CWR22Rv1, and (C) PC-3 Xenograft Studies. Supplementary Figure S3. In Vivo Activity of Isotype Control in CWR22Rv1 the Xenograft Model. Supplementary Figure S4. Cytotoxicity of the Warheads and Their Associated ADCs. Supplementary Figure S5. gamma-H2AX IHC Results. Supplementary Figure S6. Body weight measurements from a representative cell line xenograft and a LuCaP PDX in vivo activity studies. Supplementary Figure S7. Hematology Parameters (Males) following MEDI3726 Administration at 0 (control) & 0.6 mg/kg.
Authors: Song Cho, Francesca Zammarchi, David G. Williams, Carin E.G. Havenith, Noel R. Monks, Peter Tyrer, Francois D'Hooge, Ryan Fleming, Kapil Vashisht, Nazzareno Dimasi, Francois Bertelli, Simon Corbett, Lauren Adams, Halla W. Reinert, Sandamali Dissanayake, Charles E. Britten, Wanda King, Karma Dacosta, Ravinder Tammali, Kevin Schifferli, Patrick Strout, Martin Korade, Mary Jane Masson Hinrichs, Simon Chivers, Eva Corey, He Liu, Sae Kim, Neil H. Bander, Philip W. Howard, John A. Hartley, Steve Coats, David A. Tice, Ronald Herbst, Patrick H. van Berkel
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362534720